fbpx Skip to main content

BioCommunique Article

Survey results will better guide Biocom’s Return to Work Task Force in devising a plan to help the industry move forward.

Biocom Releases Results of Second Survey to Better Understand Testing and Resources

  • 2020-05-15T19:00:00.000+0000
  • California
  • Author: Lauren Panetta

After weeks of abiding by the stay-at-home order issued by California and social-distancing measures, which have been largely effective in slowing the spread of COVID-19, our state is gradually and cautiously shifting toward reopening businesses. After almost eight weeks after imposing a statewide lockdown on March 19th, Governor Newsom has authorized enclosed shopping centers, strip malls, and some offices to reopen.

To fully understand testing capacity and resource needs, Biocom’s Task Force launched a second survey, capturing the sentiments of nearly 100 life science companies throughout California. The results will better guide the Task Force in devising a plan to lead the industry forward.

The data points and key trends that stood out from the responses collected include the following:

  • 38% of companies indicated that their biggest concern about returning to work is the availability of testing
  • 93% of companies say the pandemic has somewhat or significantly affected business
  • 49% don't have an EH&S Manager focused on pandemic protocols
  • Only 2% of companies are currently testing and 30% would like to if additional protocol resources were provided
  • 30% of companies would like to test their employees weekly: 11% daily, 8% monthly, 2% one time, 28% only if experiencing symptoms
  • 44% of companies aren't planning to test due to lack of guidance

infographic_survey2_COVID_testing_social.jpg

As companies begin to reopen, the appropriate guidance and safety measures will be critical to ensure the wellbeing of all life science employees. Biocom’s Return to Work Task Force, made up of 50 board-level leaders from companies such as Thermo Fisher Scientific, Celgene, Illumina, Synthetic Genomics, and Gilead, has organized subgroups to cover several different aspects including sampling, testing, environmental health and safety, human resources, coordination with government, and scientific review.

The group has been conducting daily meetings with industry leaders, government officials, and trusted service providers to understand the most important needs of our life science industry. In the coming weeks, Biocom will be delivering a wide spectrum of resources to fully support our members as we move through Governor Newsom’s four stages for easing California’s stay-at-home orders.